Skip to main
  1. Stocks
  2. Surrozen
  3. Forecast
SRZN

Surrozen (SRZN) Stock Forecast & Price Target

Surrozen (SRZN) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Surrozen is viewed favorably because its lead asset SZN-8141 combines Wnt agonism with anti-VEGF activity, aiming to address the durability and efficacy gaps seen with current retinal therapies in DME and potentially other retinal diseases. The thesis is strengthened by Merck’s positive BRUNELLO results, which validate Wnt biology in the retina, while Surrozen’s expanded Phase 2a DUET study from n=60 to n=150 and inclusion of both treatment-naive and treatment-experienced patients should improve dose selection and create a more robust clinical dataset. With first DME patients dosed, topline Phase Ib data still expected in 2H27, Phase IIa results guided for 2028, and an anticipated YE27 net cash position supporting development, the company has multiple value-driving catalysts ahead.

Bears say

Surrozen is a clinical-stage biotech facing elevated fundamental risk because its lead retinal assets, including SZN-8141 and SZN-8143, still have unproven clinical benefit while delays in IND-enabling studies, unexpected toxicity, or broader development setbacks could derail progress. The investment case is further weakened by the failure of the Phase Ib/IIa DUET study in DME and the possibility that Merck’s Restoret Phase IIb/III study could fail, which would hurt confidence in the Wnt agonist class in retinal disease. With the retinal disease market described as extremely competitive and Surrozen needing substantial financing for development and commercialization, any inability to raise capital on favorable terms could pressure the stock.

Surrozen (SRZN) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Surrozen and is not a guaranteed prediction by Public.com or investment advice.

Surrozen (SRZN) Analyst Forecast & Price Prediction

Get the latest Surrozen (SRZN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Surrozen (SRZN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Surrozen (SRZN) Forecast

Analysts have given Surrozen (SRZN) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Surrozen (SRZN) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $65.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $65.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Surrozen (SRZN)


Surrozen (SRZN) Analyst Forecast & Price Prediction

Get the latest Surrozen (SRZN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Surrozen (SRZN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover SRZN stock data and trends